The outcome of TGF β antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and pro-progression activities of TGFβ.

CONCLUSIONS: Contrary to dogma, tumor suppressive responses to TGF-β are retained in some advanced metastatic tumors. Safe deployment of TGF-β antagonists in the clinic will require good predictive biomarkers.
PMID: 31582516 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 2, 2019 Category: Cancer & Oncology Authors: Yang Y, Yang H, Tang B, Wu AML, Flanders KC, Moshkovich N, Weinberg DS, Welsh MA, Weng J, Ochoa HJ, Hu TY, Herrmann MA, Chen J, Edmondson EF, Simpson RM, Liu F, Liu H, Lee M, Wakefield LM Tags: Clin Cancer Res Source Type: research